Epigenetic changes may influence the clinical course of glioblastoma, most notably in the case of O6-methylguanine-DNA methyltransferase promoter methylation influencing response to temozolomide treatment.6 Additionally, data were collected from patients receiving care at leading cancer centers and therefore may not be representative of the broader population. This evidence concerns the gene MGMT and cancer.